Standard Biotools Inc (LAB) Stock Price, Quote & News

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 266 6000

Fax: 650 871 7152

Website: www.standardbio.com

Address:

50 Milk Street, 10th Floor, Boston, United States

FutureScout Jul. 1 at 9:32 PM

$LAB worked because the setup had time to mature. Binance Alpha TGEs and the AI narrative can catch a bid, but the real edge is capital + patience. Most traders want the move before the base is even built. I held $LAB for over 6 months before it pumped — that’s the part many can’t stomach.

1 · Reply

WallStreetWoof Jul. 1 at 5:57 PM

$LAB Pleasantly surprised by today's action. Still along way to go, and I am sure there will be resistance at the 1 dollar mark...can only hope merger will result in higher share price....

0 · Reply

OrganizedChaos Jun. 30 at 12:36 AM

$LAB you were warned!! http://stocktwits.com/OrganizedChaos/message/629055364

1 · Reply

SnowyDingo Jun. 29 at 8:43 PM

$LAB too much bearishness for no reason, the insiders saw something that no one else did. It's time to load up

1 · Reply

stopwatchinme Jun. 29 at 1:59 PM

$LAB Patience...for now $FITY is on the move.

0 · Reply

SnowyDingo Jun. 26 at 9:44 PM

$LAB 35M traded shares? Something's fishy!

1 · Reply

Jkpga Jun. 26 at 7:09 PM

$LAB I doubt this merger will even happen

1 · Reply

lousyknees Jun. 25 at 9:39 PM

$LAB This is absolutely the most disfunctional stock that I've ever invested in. Where is the bottom? .74 cents or lower? I'm so disappointed with Standard Bio. Looks like they just couldn't get it together and gave up. Still a holdover from Fluidigm (2020), and that was a total cluster. The whole thing stinks of desperation with no regard to the stockholders.

2 · Reply

beckphan08 Jun. 25 at 8:08 PM

$LAB did this turn into a scam company once Casdin got involved ?

0 · Reply

Jkpga Jun. 24 at 7:29 PM

$LAB complete garbage

1 · Reply

Standard BioTools Transcript: AGM 2026

Jun 17, 2026, 8:30 AM EDT - 17 days ago

LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers

RAMP

Jun 11, 2026, 7:00 AM EDT - 23 days ago

Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District

Jun 11, 2026, 7:00 AM EDT - 23 days ago

Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects

2026-06-08T11:42:28.000Z - 26 days ago

Standard BioTools, Treeline Biosciences to combine in all-stock transaction

ILMN

Jun 8, 2026, 7:30 AM EDT - 26 days ago

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Jun 8, 2026, 7:30 AM EDT - 26 days ago

Standard BioTools Transcript: M&A announcement

Jun 8, 2026, 7:30 AM EDT - 26 days ago

Standard BioTools Press release: M&A announcement

Jun 8, 2026, 7:30 AM EDT - 26 days ago

Standard BioTools Slides: M&A announcement

May 5, 2026, 4:05 PM EDT - 2 months ago

Standard BioTools Reports First Quarter 2026 Financial Results

May 5, 2026, 4:00 PM EDT - 2 months ago

Standard BioTools Earnings release: Q1 2026

May 5, 2026, 4:00 PM EDT - 2 months ago

Standard BioTools Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Standard BioTools Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Standard BioTools Proxy statement: Proxy filing

2026-02-24T21:17:26.000Z - 4 months ago

Standard BioTools reports Q4 EPS 5c vs (9c) last year

2026-02-24T21:16:44.000Z - 4 months ago

Standard BioTools sees FY26 revenue $80M-$85M, consensus $79.73M

Feb 24, 2026, 4:10 PM EST - 4 months ago

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 4:00 PM EST - 4 months ago

Standard BioTools Annual report: Q4 2025

Feb 24, 2026, 4:00 PM EST - 4 months ago

Standard BioTools Earnings release: Q4 2025

Feb 10, 2026, 7:00 AM EST - 5 months ago

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

2026-01-30T14:16:09.000Z - 5 months ago

Standard BioTools completes sale of SomaLogic to Illumina

ILMN

Jan 30, 2026, 9:09 AM EST - 5 months ago

Standard BioTools Completes Sale of SomaLogic to Illumina

2026-01-08T12:05:40.000Z - 6 months ago

Standard BioTools sees Q4 revenue from cont. ops. $24M, consensus $18.5M

Jan 8, 2026, 7:00 AM EST - 6 months ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Nov 19, 2025, 11:30 AM EST - 8 months ago

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Nov 10, 2025, 12:15 PM EST - 8 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN

2025-11-05T13:50:39.000Z - 8 months ago

Standard BioTools price target lowered to $1.35 from $1.55 at TD Cowen

Nov 4, 2025, 4:05 PM EST - 8 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:00 PM EST - 8 months ago

Standard BioTools Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 8 months ago

Standard BioTools Earnings release: Q3 2025

Oct 21, 2025, 7:00 AM EDT - 9 months ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Sep 3, 2025, 9:15 AM EDT - 10 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN

2025-08-13T10:05:55.000Z - 11 months ago

Standard BioTools downgraded to Hold from Buy at TD Cowen

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Standard BioTools Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Standard BioTools Earnings release: Q2 2025

2025-08-11T20:16:09.000Z - 11 months ago

Standard BioTools reports Q2 EPS (9c), consensus (4c)

2025-08-11T20:15:49.000Z - 11 months ago

Standard BioTools sees FY25 revenue $165M-$175M, consensus $169.13M

Aug 11, 2025, 4:01 PM EDT - 11 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results

2025-08-06T11:30:45.000Z - 11 months ago

Standard BioTools, Precision Health, Singapore launch proteomic collaboration

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

2025-06-23T17:12:37.000Z - 1 year ago

Standard BioTools to sell SomaLogic to Illumina for $350M upfront payment

ILMN

2025-06-23T17:10:18.000Z - 1 year ago

Illumina to acquire SomaLogic for $350M in cash

ILMN

Jun 23, 2025, 7:13 AM EDT - 1 year ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN

Jun 23, 2025, 7:05 AM EDT - 1 year ago

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

2025-05-30T11:15:44.000Z - 1 year ago

Standard BioTools to host inaugural ‘Proteomics Roundtable’ series

May 30, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Slides: Q1 2025

2025-05-06T20:16:39.000Z - 1 year ago

Standard BioTools reports Q1 EPS (7c), consensus (4c)

May 6, 2025, 4:01 PM EDT - 1 year ago

Standard BioTools Reports First Quarter 2025 Financial Results

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Standard BioTools Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Standard BioTools Proxy statement: Proxy Filing

2025-04-24T11:16:19.000Z - 1 year ago

Standard BioTools announces new product innovations at AACR 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Transcript: KeyBanc Annual Health Care Forum 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Standard BioTools Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 4:01 PM EST - 1 year ago

Standard BioTools to Participate in Upcoming Investor Conferences

2025-02-27T09:40:45.000Z - 1 year ago

Standard BioTools downgraded to Sector Weight from Overweight at KeyBanc

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Slides: Q4 2024

2025-02-26T21:27:29.000Z - 1 year ago

Standard BioTools reports Q4 EPS (9c), consensus (3c)

2025-02-26T21:26:38.000Z - 1 year ago

Standard BioTools sees FY25 revenue $165M-$175M, consensus $186.93M

Feb 26, 2025, 4:01 PM EST - 1 year ago

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Standard BioTools Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Standard BioTools Slides: FY 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 8:00 AM EST - 1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 19, 2024, 3:30 AM EST - 1 year ago

Standard BioTools Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 3:30 AM EST - 1 year ago

Standard BioTools Slides: FY 2024

Nov 12, 2024, 4:15 PM EST - 1 year ago

Standard BioTools Transcript: UBS Global Healthcare Conference 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Quarterly report: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings release: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Slides: Q3 2024

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Standard BioTools Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Standard BioTools Transcript: UBS Genomic Medicine Summit

Aug 13, 2024, 9:00 AM EDT - 2 years ago

Standard BioTools Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings Call Transcript: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Quarterly report: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings release: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Slides: Q2 2024

Jul 31, 2024, 4:02 PM EDT - 2 years ago

Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 8:01 AM EDT - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jun 5, 2024, 2:30 PM EDT - 2 years ago

Standard BioTools Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 28, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 21, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings release: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Slides: Q1 2024

May 8, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:01 AM EDT - 2 years ago

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Apr 3, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Mar 19, 2024, 10:30 AM EDT - 2 years ago

Standard BioTools Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 18, 2024, 8:12 AM EDT - 2 years ago

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Mar 6, 2024, 1:30 PM EST - 2 years ago

Standard BioTools Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Annual report: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Earnings release: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Slides: Q4 2023

Feb 28, 2024, 4:01 PM EST - 2 years ago

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 7, 2024, 8:30 AM EST - 2 years ago

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Feb 2, 2024, 7:00 AM EST - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jan 19, 2024, 7:00 AM EST - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jan 19, 2024, 7:00 AM EST - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jan 8, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Jan 5, 2024, 8:46 AM EST - 2 years ago

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 9:44 PM EST - 2 years ago

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Dec 31, 2023, 2:10 PM EST - 2 years ago

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

FutureScout Jul. 1 at 9:32 PM

1 · Reply

WallStreetWoof Jul. 1 at 5:57 PM

$LAB Pleasantly surprised by today's action. Still along way to go, and I am sure there will be resistance at the 1 dollar mark...can only hope merger will result in higher share price....

0 · Reply

OrganizedChaos Jun. 30 at 12:36 AM

$LAB you were warned!! http://stocktwits.com/OrganizedChaos/message/629055364

1 · Reply

SnowyDingo Jun. 29 at 8:43 PM

$LAB too much bearishness for no reason, the insiders saw something that no one else did. It's time to load up

1 · Reply

stopwatchinme Jun. 29 at 1:59 PM

$LAB Patience...for now $FITY is on the move.

0 · Reply

SnowyDingo Jun. 26 at 9:44 PM

$LAB 35M traded shares? Something's fishy!

1 · Reply

Jkpga Jun. 26 at 7:09 PM

$LAB I doubt this merger will even happen

1 · Reply

lousyknees Jun. 25 at 9:39 PM

2 · Reply

beckphan08 Jun. 25 at 8:08 PM

$LAB did this turn into a scam company once Casdin got involved ?

0 · Reply

Jkpga Jun. 24 at 7:29 PM

$LAB complete garbage

1 · Reply

WallStreetWoof Jun. 20 at 3:26 AM

$LAB Cash per share prior to the merger was 1.17 and book value 1.44. Announce merger and stock plummets to ~0.80. How is that creating value in the near or long term... ? Payout of 50M for sale of existing LAB operations is roughly 0.13/share.... not even close to 1.17 ro 1.44....

1 · Reply

WallStreetWoof Jun. 20 at 3:16 AM

$LAB Why is TreeLIne considered a secretive company ? Is it because come of it's candidate drugs are licensed from, (and probably made in), China ? (probably made in China) "Treeline acquired rights to a second drug, TLN-254, from Hengrui Pharmaceuticals in 2023. That drug is approved in China for use in patients with relapsed or refractory peripheral T-cell lymphoma." How many of the pipeline candidate drugs are made in China ? Maybe this was a backdoor way for China to launch products in the U.S. Company needs to be less secretive. imho

3 · Reply

ThatsNoMoon Jun. 18 at 1:00 PM

$LAB took a flyer on this. Core thesis: LAB shareholders are buying into Treeline at a meaningful discount to the negotiated deal value, with Standard BioTools contributing about $450M of net cash, the combined company expected to have >$900M cash, and legacy LAB holders expected to own about 16% of the combined Treeline company. The combined company is expected to operate as Treeline Biosciences after close.

1 · Reply

OriginalTradeonrumor Jun. 17 at 8:38 PM

$LAB sold most of mine in upper .80’s and .90’s—have a flyer position and will hold until .90’s again and or news…too many other opportunities out there 🙂

0 · Reply

beckphan08 Jun. 16 at 11:13 AM

$LAB this truly is the turd in the punch bowl.

0 · Reply

SuperGreenToday Jun. 16 at 1:52 AM

$LAB Share Price: $0.85 Contract Selected: Nov 20, 2026 $0.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.16 – $0.19 Potential Upside: 77% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Lussu1986 Jun. 16 at 1:14 AM

$LAB Have to say it's pretty discouraging how things have played out. I had confidence in management as experienced operators and could come up with a better plan than punting the whole thing into a biopharm venture deal with a messy tbd structure. Treeline appears like a solid story with potential but tough to find any near term catalysts and given many shareholders have been dragged along with nothing to show for it and various managements from Fluidigm to LAB have made millions it would be nice for the shareholders have something to show for this. Not holding my breath for CVR payments because after sale and closing costs, severances etc.. guessing there will be little to distribute. I'm definitely reducing positions size and may exit completely.

0 · Reply

OriginalTradeonrumor Jun. 11 at 2:31 PM

$LAB I loved the 80’s…but it’s good to be in the 90’s 😁

1 · Reply

debbiekatz Jun. 9 at 9:10 PM

1 · Reply

Ozyil Jun. 9 at 7:48 PM

$LAB 1+

0 · Reply

Ozyil Jun. 9 at 7:00 PM

$LAB back to 1+ dollar

0 · Reply

Ozyil Jun. 9 at 6:27 PM

$LAB why is this green? is this dip buy?

0 · Reply

Market Cap	356.37M
Revenue (ttm)	85.33M
Net Income (ttm)	-74.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-87.78%
Debt to Equity Ratio	0.00

Volume	4,448,100
Avg Vol	3,869,000
Day's Range	N/A - N/A
Shares Out	390.37M
Stochastic %K	93%
Beta	1.42
Analysts	Sell
Price Target	$1.55